| INTRODUCTION
Lung cancer is the most deadly cancer worldwide, often diagnosed when locally advanced (stage IIIB) or with distant metastases (stage IV).
In 2012, lung cancer was responsible for 1.6 million deaths, amounting to about 20% of all cancer-related deaths (International Agency for Research on Cancer, 2014). The 5-year survival rates for lung cancer in [2005] [2006] [2007] [2008] [2009] ranged from 15% to 20% in most countries (Cheng et al., 2016; Wang et al., 2013) . Non-small cell lung cancer (NSCLC) is the most common histological type, comprising approximately 80%-85% of cases (Herbst, Heymach, & Lippman, 2008; Reck, Heigener, Mok, Soria, & Rabe, 2013) . While the distribution of histologies varies among countries, the two most common NSCLC histological subtypes are squamous cell carcinoma and the non-squamous cell carcinomas, of which adenocarcinoma is the most common. However, a variable proportion of NSCLC remains unclassified histologically when the diagnosis relies on cytology or small biopsies (Travis et al., 2015) .
The majority of patients with lung cancer have a history of smoking, including from 65%-90% of men and 25%-70% of women, depending on the country (Cheng et al., 2016) .
Many advances have been made in lung cancer screening, diagnostics, and therapy since the turn of the last century. Discoveries of targetable gene mutations and the development of targeted therapies, as well as immunotherapies such as the programmed death-1 (PD-1) and PD ligand-1 (PD-L1) inhibitors, have contributed to changes in the management of NSCLC. The potential now exists for personalised therapy based on histology and biomarker findings, raising hopes of improved outcomes for patients with lung cancer (Novello et al., 2016 ).
An understanding of real-world treatment patterns for NSCLC can provide context for the rapidly changing landscape of NSCLC therapy.
Moreover, patients enrolled in randomised controlled trials (RCTs) do not represent patients seen in routine clinical practice who are often more diverse, have more comorbidities, and may not be eligible to participate in RCTs (Murthy, Krumholz, & Gross, 2004 Histology, n (%) 42 (24) 121 (70) 11 (6) 33 (16) 140 (69) 29 (14) 28 (20) 108 (78) 3 (2) Male patients, n (%) 38 (90) 78 (64) 7 (64) 30 (91) 104 (74) 21 (72) 22 (79) The "Unknown" category includes patients for whom data were incomplete or missing. Percentages may not total 100 because of rounding. BMI, body mass index; COPD, chronic obstructive pulmonary disease; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; NSCC, non-squamous cell carcinoma; Unk, unknown histology. a BMI categories were defined as follows (in kg/m 2 ): underweight, ≤18.49; normal, 18.50-24.99; overweight, 25.00-29.99; obese, ≥30.00. b Three patients in the squamous cohort in Germany were recorded as being smokers without a specification as to current or former smoking; therefore, these patients were included in the unknown category. c Comorbidities are reported for patients with non-missing data, including 153, 169 and 128 in Italy, Spain and Germany, respectively.
T A B L E 2 Demographic and clinical characteristics of patients with advanced NSCLC in Australia, Korea, Taiwan and Brazil 30 (14) 161 (77) 17 (8) 30 (20) 113 (75) 7 (5) 16 (7) 201 (93) 35 (20) 132 (75) 8 (5) Male patients, n (%)
24 (80) 90 (56) 11 (65) 28 (93) 71 (63) 5 (71) 13 (81) 90 (45) 26 (74) 83 ( 124 ( 11 (7) 1 (6) 30 (100) 113 (100) 7 (100) 16 (100) 200 ( 12 (11) 2 (29) 4 (25) 13 (7) 3 (9) 11 (8) 1 (13) Normal 17 (57) 76 (47) 7 (41) 24 (80) 77 (68) 4 (57) 7 (4) 132 (66) 19 (54) 56 (42) 6 (75) 8 (27) 55 (34) 5 (29) 5 (17) 18 (16) 1 (14) 3 (19) 46 (23) 9 (26) 38 ( 38 (24) 6 (35) 21 (70) 28 (25) 2 (29) 4 (25) 16 (8) 8 (23) 18 (14) 0 Former 18 (60) 98 (61) 9 (53) 6 (20) 36 (32) 2 (29) 6 (37) 45 (22) 24 (69) 80 (61) 6 (75) Never 2 (7)
Overweight
22 (14) 1 (6) 3 (10) 45 (40) 3 (43) 5 (31) 138 (69) 3 (9) 31 (24) 1 ( 15 (8) 4 (12) 14 ( 1 (17) 3 (21) 8 (4) 7 (21) 18 (16) 2 (29) Diabetes mellitus 6 (24)
17 (12) 2 (13) 5 (20) 19 (20) 1 (17) 2 (14) 39 (20) 6 (18) 19 (17) 2 (29) The "Unknown" category includes patients for whom data were incomplete or missing. Percentages may not total 100 because of rounding. BMI, body mass index; COPD, chronic obstructive pulmonary disease; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; NSCC, non-squamous cell carcinoma; Unk, unknown histology. Japan are reported in a separate publication (Kato et al., 2016) .
| METHODS

| Study design and patients
This observational, non-interventional study drew on de-identified patient data abstracted from medical records at academic and com- an eligibility criterion, with staging done according to the latest TNM classification (Edge et al., 2010; Sobin, Gospodarowicz, & Wittekind, 2009 Other exclusion criteria were a concomitant or prior history of malignancy and participation in any cancer-related clinical trial.
Eligible patients were identified via medical records at each participating centre. The selection of eligible patients began from the end of the eligibility period, working backwards in time within that period until suitable numbers of patients were reached for each centre. The date of initiation of first-line therapy for each patient after confirmation of the diagnosis was defined as their index date. Patients were followed from the index date until the record abstraction date (in 2015-2016) , defined as the first site initiation in each country, or until death, whichever occurred first.
The study protocol was approved by the appropriate institutional review board or independent ethics committee for each study site.
Informed consent was collected for patients from Italy, Spain, Germany and Brazil who were alive at the time of chart abstraction. Informed consent was not required for working with de-identified retrospective data in the other countries.
| Data collection and outcomes
Each patient's medical record was given a unique number, and all identifiable patient data were restricted to the site and treating physician.
Electronic case report forms were used to abstract de-identified data from the medical records regarding patient demographic characteris- resource occurred secondary to a treatment-related adverse event.
As part of the protocol, investigators were provided with NSCLC staging guidelines according to the TNM classification (Edge et al., 2010; Sobin et al., 2009 ) and with treatment response criteria based on the Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) (Eisenhauer et al., 2009) . Performance status on the index date was assessed using the Eastern Cooperative Oncology Group (ECOG) score (Oken et al., 1982) or the Karnofsky scale (Buccheri, Ferrigno, & Tamburini, 1996) . The duration of treatment in each line of systemic therapy was calculated in days as [the stop date of treatment linestart date of treatment line +1 day].
Because this was a retrospective study, all patients were assessed and treated according to the usual practice of the treating physician.
| Statistical analyses
Data from medical records were analysed descriptively and reported using summary statistics by country. Overall survival (OS) from initiation of first-and second-line therapy, by histological classification and by treatment regimen, was estimated using the Kaplan-Meier product-limit method.
This was an observational study with no a priori hypothesis testing; therefore, we did not undertake a formal calculation of sample size and receive first-line therapy will receive second-line therapy (Bischoff et al., 2010; Gerber et al., 2011; Vergnenegre et al., 2012) , and 22% of patients who receive second-line therapy will receive third-line therapy (Pan, Mallick, Dhanda, & Nadler, 2013) .
All analyses were carried out using SAS version 9.3 (SAS Institute, Cary, NC, USA).
| RESULTS
| Patients
Medical records were abstracted from three to 13 study centres in each of the seven countries. All study sites in Australia and Taiwan were centres affiliated with an academic institution; in the other countries, study sites were a mix of academic and community oncology clinics (details in Table S1 ). Index dates (dates of first-line therapy initiation) ranged from January 19, 2011, to July 1, 2014, and record abstraction dates ranged from April 24, 2015, in Australia to May 27, 2016, in Brazil (Table S1 ).
The study population of 1265 patients included from 139 patients (Germany) to 217 patients (Taiwan) in each country. The distribution of squamous and non-squamous NSCLC was similar among the countries, with approximately three-quarters being of non-squamous histology, except in Taiwan (93%). The proportion of patients with unknown histology was more variable, with 2%-8% in most countries except Spain (14%) and Taiwan (none ; Tables 1 and 2 ). Patients in the squamous cohorts tended to be slightly older on average, as well as more likely to be male and current or ex-smokers, than those in the non-squamous cohorts. From 4% (Korea) to 33% (Germany) of patients had concomitant chronic obstructive pulmonary disease (COPD). In Taiwan, patients with non-squamous carcinoma were predominantly female (55%) and never-smokers (69%), both higher percentages compared with other countries (Tables 1 and 2 ).
| NSCLC-related characteristics
The majority of patients presented with Stage IV NSCLC (78% to 93%
by country), with the highest proportions in the non-squamous cohorts (Tables 3 and 4 ). The diagnosis was made most commonly by biopsy or by both biopsy and cytology; however, the diagnosis relied on cytology for a substantial percentage of patients in Australia (33%) and Spain (31%). The most common locations of metastases are summarised according to histology, by country, in Tables S2 and S3 . The proportion of patients who had brain metastases in each country was from 13% (Germany) to 27% (Korea).
The Eastern Cooperative Oncology Group (ECOG) performance status at the index date was available for three-quarters or more of patients in all countries except Italy (57%), Spain (64%) and Korea (45%).
Of the patients with a recorded ECOG PS, over 70% in each country had a score of 0-1, ranging from 71% of patients in Spain to 96% in Germany (Tables 3 and 4) . Stage at diagnosis, n (%) IIIB 5 (12) 7 (6) 1 (9) 10 (30) 6 (4) 1 ( Results for the other patients tested were mostly negative, and a small minority were inconclusive or unknown.
T A B L E 3 NSCLC-related characteristics of patients with advanced NSCLC in Italy, Spain and Germany
| Molecular testing for predictive biomarkers
In the non-squamous cohorts, biomarker testing was done for the majority of patients, ranging from 54% in Brazil to 91% in Taiwan   (Tables 3 and 4 (Tables 3 and 4 ).
In the squamous cohorts, less than a quarter of patients in each country were tested for biomarkers except in Spain (42%). From 0 to two patients with squamous NSCLC in each country had EGFRpositive tumours; none had ALK-positive tumours (Tables 3 and 4) .
| Systemic therapy for NSCLC
After receiving first-line therapy in accordance with study enrolment criteria, from 46% (Germany) to 71% (Taiwan) of patients in each country received second-line therapy and then 17% (Brazil) to 42%
(Taiwan) received third-line therapy. The most common first-, secondand third-line regimens administered in each country are outlined according to regimen category in Tables 5 and 6 together with number of cycles administered and treatment duration. Treatment regimens are further detailed, by histology, in Tables S4-S7 .
Platinum-based regimens were the most common first-line therapy in every country except in Taiwan, where EGFR tyrosine kinase inhibitors (TKIs), particularly gefitinib, were the most common first-line therapy. Carboplatin and cisplatin were administered in roughly equal proportions in most countries except in Australia and
Brazil, where carboplatin-based regimens predominated (Tables 5   and 6 ). (40) 31 (19) 1 (6) 14 (47) 12 (11) Results for the other patients tested were mostly negative, and a small minority were inconclusive or unknown.
T A B L E 5 Treatment patterns for first-, second-and third-line therapy, by histology, in Italy, Spain and Germany (100) 121 (100) 11 (100) 33 (100) 140 (100) 29 (100) 28 (100) 108 (100) 3 (100) Platinum-based combination 31 (74) 101 (84) 8 (73) 29 (88) 122 (87) 25 (86) 28 (100) 91 (84) 3 (100) Carboplatin-based
16 (38) 48 (40) 7 (64) 10 (29) 59 (42) 13 (45) 14 (50) 46 ( 18 (53) 61 (43) 12 (42) 14 (50) 42 ( (49) 141 (136) 200 (188) 109 (120) 187 (175) 111 (77) 128 (118) 170 (181) 314 ( (45) 43 (36) 3 (27) 14 (42) 37 (26) 9 (31) 5 (18) 34 ( (52) 61 (50) 4 (36) 15 (46) 83 (59) 15 (52) 22 (84) 68 (64) 3 (100) >6 cycles 0 14 (12) 4 (36) 4 (12) 19 (14) 5 (17) 1 ( 18 (8) 21 (18) 25 (7) 21 (11) 23 (14) 18 (7) 22 (7) 22 (12) 22 (1) Second-line therapy, n (%)
19 (45) 75 (62) 6 (55) 12 (36) 70 (50) 10 (34) 17 (59) 45 (42) 1 ( 1 (8) 14 (20) 1 (10) 5 (29) 9 ( (79) 37 (49) 1 (17) 3 (25) 30 (43) 6 (60) 9 (53) 14 ( (49) 93 (109) 129 (92) 74 (65) 90 (69) 104 (157) 66 (64) 120 ( 39 (51) 3 (50) 7 (58) 26 (50) 7 (70) 11 (65) 21 ( 4 (33) 25 (36) 2 (20) 5 (29) 12 (27) 1 (100) >6 cycles 2 (11) 7 (9) 1 (17) 1 (8) 8 (11) 1 (10) 1 (6) 7 ( 21 (9) 21 (10) 28 (7) 23 (9) 23 (8) 21 (11) 24 (12) 24 (8) 21
Third-line therapy, n (%)
8 (19) 32 (26) 4 (36) 7 (21) 35 (25) 3 (10) 8 (28) 22 ( (63) 3 (75) 3 (43) 10 (29) 2 (67) 3 (38) 9 ( 91 (74) 76 (51) 93 (80) 74 (64) 64 (24) 135 (138) 202 ( 16 (50) 2 (50) 4 (57) 24 (69) 3 (100) 4 (50) 5 ( 16 (9) 23 (10) 19 (9) 26 (10) 23 (9) 28 (19) 26 (13) 25 (8) 0 Data are n (%) unless otherwise specified. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; NSCC, non-squamous cell carcinoma; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor; Unk, unknown histology.
a
The five systemic therapy categories were defined as follows:
• Platinum-based combination: regimen with two or more anticancer therapies including carboplatin or cisplatin.
• Non-platinum combination: regimen with two or more anticancer therapies not including carboplatin or cisplatin (can contain bevacizumab in combination with other non-platinum drug).
• Single agent: regimen of one anticancer drug that was not an EGFR or ALK tyrosine kinase inhibitor (TKI).
• EGFR/ALK TKI: monotherapy with anti-EGFR (erlotinib, gefitinib, afatinib) or anti-ALK agent (crizotinib, ceritinib).
• Other NSCLC anticancer agent: any other agent not included in the prior categories, e.g. TS-1 (oral anticancer drug composed of tegafur, gimestat and otastat potassium at a molar ratio of 1:0.4:1).
b
No patient received an "other NSCLC anticancer agent" in first line. (100) 161 (100) 17 (100) 30 (100) 113 (100) 7 (100) 16 (100) 201 (100) 35 (100) 132 (100) 8 (100) Platinum-based combination 26 (87) 131 (81) 15 (88) 30 (100) 83 (74) 5 (71) 8 (50) 33 (17) 35 (100) 121 (92) 7 (88) Carboplatin-based 22 (73) 115 (71) 14 (82) 20 (67) 43 (38) 3 (43) 4 (25) 6 (3) 23 (65) 87 (66) 6 (75) Cisplatin-based 3 (10) 15 (9) 1 (6) 10 (33) 40 (35) 2 (29) 4 (25) 26 (13) 12 (34) 32 (24) 1 (13) Carboplatin and cisplatin (1) 1 (14) 3 (19) 25 ( (78) 132 (162) 69 (61) 71 (37) 115 (163) 27 (20) 136 (169) 263 (207) 92 (75) 112 (111) 52 (19) Available cycle data, n (50) 67 (42) 9 (47) 9 (30) 48 (43) 6 (57) 10 (63) 49 (24) 13 (37) 41 (31) 8 (63) 4-6 cycles 14 (47) 80 (50) 8 (47) 16 (53) 42 (43) 1 (14) 3 (19) 52 (26) 22 (63) 84 (64) 3 ( Mean (SD) 19 (10) 21 (28) 17 (7) 18 (11) 19 (20) 18 (12) 49 (95) 39 (65) 18 (7) 19 (17) 16 (3) Second-line therapy, n (%)
14 (47) 100 (61) 14 (82) 19 (63) 74 (65) 3 (43) 13 (81) 142 (71) 16 (46) 71 (54) 4 (50) Platinum-based combination 2 (14) 19 (19) 1 (7) 1 (5) 10 (14) 0 3 (23) 44 (31) 1 (6) 13 (18) 0 Carboplatin-based 2 (14) 19 (19) 1 ( (15) 34 (24) 1 (6) 5 ( (64) 60 (60) 8 (57) 7 (37) 24 (32) 1 (33) 6 (46) 44 (31) 14 (88) 51 (72) 3 (75) EGFR/ALK TKI 3 (21) 21 (21) 4 (29) 8 (42) 40 (54) 2 (67) 1 (8) 27 (19) 1 (6) 6 ( (34) 120 (137) 97 (127) 83 (168) 110 (132) 84 (126) 96 (59) 175 (177) 52 (42) 80 (87) 212 (300) Available cycle data, n (86) 48 (48) 8 (57) 15 (79) 46 (62) 2 (67) 7 (54) 61 (43) 11 (69) 46 (65) 2 ( (14) 28 (28) 3 (21) 3 (16) 9 (12) 0 6 (46) 36 (25) 5 (31) 18 (25) 1 (25) >6 cycles 0 21 (21) 3 (21) 1 (5) 17 (23) 1 ( 18 (10) 21 (9) 18 (12) 23 (12) 24 (10) 24 (14) 29 (20) 5 (5.5)
17 (8) 21 (18) 27 (22) Third-line therapy, n (%)
4 (13) 40 (25) 8 (47) 10 (23) 46 (41) 3 (43) 7 (44) 84 (42) 6 (17) 22 (17) 2 (25) Platinum-based combination 1 (25) 6 (15) 1 (13) 1 (10) 3 (7) 0 1 (14) 2 (2) 1 (17) 3 ( (25) 14 (35) 2 (25) 4 (40) 28 (61) 2 (67) 2 (29) 24 (29) 4 (67) 9 (41) 2 (100) EGFR/ALK TKI 1 (25) 13 (33) 5 (63) 4 (40) 12 (26) 1 (33) 4 (57) 44 (52) 1 (17) 7 ( (60) 133 (145) 91 (87) 27 (20) 80 (127) 77 (114) 47 (35) 126 (133) 85 (72) 102 (61) 50 (40) Available cycle data, n 22 (55) 4 (50) 10 (100) 31 (67) 2 (67) 5 (72) 47 (56) 4 (67) 8 (36) 1 (50) 4-6 cycles 3 (50) 10 (25) 2 ( (14) 17 (20) 1 (17) 6 (27) 1 ( 22 (11) 25 (8) 24 (9) 22 (11) 17 (11) 25 (16) 37 (33) 40 (51) 23 (8) 25 (7) 15 (6) Data are n (% of non-missing) unless otherwise specified. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; NSCC, non-squamous cell carcinoma; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor; Unk, unknown histology.
No patient received an "other NSCLC anticancer agent" in first-line, and only 1 (0.9%) patient in the Taiwan non-squamous cohort received an "other agent" in second line.
c
The duration of treatment (days) in a treatment line was calculated as [stop date of treatment line-start date of treatment line +1 day].
T A B L E 6 (Continued)
From 7% (Korea) to 32% (Spain) of patients received maintenance therapy. Table S8 summarises the numbers of patients who received continuation and switch maintenance therapy.
For second-line therapy, single agents were commonly administered, particularly in Brazil and Australia. Otherwise, the treatment patterns varied amongst the countries and according to histologies (Tables 5 and 6 ). Similarly, for third-line therapy, treatment patterns were varied, and single agents were common in Brazil, as well as in
Italy and Korea (details in Tables S4-S7 ).
| Overall survival
The median OS from initiation of first-line therapy ranged from 9.3 months in Brazil to 25.5 months in Taiwan (Table 7 ; Figure 1 ). In Italy,
Australia and Taiwan, patients in the non-squamous cohorts had markedly longer median OS than those in the squamous cohorts, whereas median OS was similar for the two histological subtypes in the other countries (per protocol, OS was not calculated for German patients).
The median OS from initiation of second-line therapy was also shortest in Brazil (5.4 months) and longest in Taiwan (15.8 months).
In all countries except Brazil, median OS from initiation of second-line therapy was longer for patients with non-squamous NSCLC than for those with squamous cell carcinoma (Table 7) .
| DISCUSSION
This multinational retrospective study found both strong similarities as regard to demographic characteristics of the non-squamous cohort, which included >50% women and never-smokers, and higher rates of EGFR mutation testing but lower rates of ALK rearrangement testing.
The NSCLC diagnostic and treatment patterns recorded in this study were largely in line with guideline recommendations during the study years. Consensus European guidelines at the time of our study eligibility period (2011 to mid-2014) recommended the histological sub-classification of NSCLC, together with EGFR testing and, beginning in 2012, ALK testing, for patients with non-squamous NSCLC and for light or never-smokers with squamous NSCLC (Besse et al., 2014; Felip, Gridelli, Baas, Rosell, & Stahel, 2011; Kerr et al., 2014; Peters et al., 2012) . For first-line therapy of metastatic NSCLC, guidelines recommended platinum-based chemotherapy, four to six cycles; while, for patients with EGFR-positive tumours, the recommendation was for an EGFR TKI as first-line therapy or as maintenance therapy, if not received as first line.
Our findings update and expand on findings of prior multinational and single-country observational (non-interventional) studies of NSCLC treatment patterns. In Europe, the reported rate of EGFR mutation testing for patients with advanced NSCLC increased over the years from 3.5% in 2006 -2008 (Moro-Sibilot et al., 2010 ), to 26% in 2009 (Schnabel et al., 2012 , and then to 50%-70% in the European countries in our study and others in Europe during the same time (2011-2014) (Gridelli et al., 2014) . Similarly, in Korea, our study shows increased use of biomarker testing, as compared with retrospective studies looking at earlier years, which reported ~40% of patients tested for EGFR mutation during the period from 2007 to 2010 Sun et al., 2013) .
Differences in national NSCLC drug approval timelines and reimbursement policies could explain some of the differences in predictive biomarker testing rates and treatment patterns among the countries in our study. In Korea and Taiwan, the percentages of patients with EGFRpositive non-squamous NSCLC were relatively higher, 40% and 68%
respectively. This is an expected finding, as the reported prevalence of EGFR mutations in lung adenocarcinoma, for example, is much higher in Asia-Pacific populations, averaging 47%, than in European populations (average, 15%) (Midha, Dearden, & Mccormack, 2015) .
Moreover, the prevalence of EGFR mutations in lung adenocarcinoma is higher in women than men and in never-smokers than ever-smokers, which could explain the high prevalence in Taiwan, where the nonsquamous cohort included 69% never-smokers and 55% women.
We found a low frequency of testing for ALK rearrangements for non-squamous NSCLC in Taiwan (2.5%) as compared with Korea (47%), likely explained by reimbursement policies and the timeline of regulatory approval of anti-ALK agents in those two countries. In Korea, the first ALK inhibitor, crizotinib, was approved in late 2011, and ALK testing was approved in January of 2013. Instead, in Taiwan, ALK testing is not subject to regulatory approval (and is not reimbursed), and drug reimbursement is based on approved indication(s). The regulatory approval of crizotinib for second-line therapy for ALK-positive NSCLC did not occur until after our study (September 2015) ; and no other ALK inhibitors were approved in Taiwan during the study. In Taiwan, of the five non-squamous tumours tested, three (60%) were ALK-positive; in Korea, the percentage was 17%. By contrast, in the European countries, one-quarter to one-third of non-squamous tumours were tested for ALK rearrangement, and 3%-5% were ALK-positive.
Routine molecular testing of squamous NSCLC was not recommended by guidelines (Felip et al., 2011; Kerr et al., 2014; Peters et al., 2012) ; however, we found that predictive biomarker testing was done for one-fifth to almost one-half of patients with squamous NSCLC in Germany (21%), Korea (23%) and Spain (42%) . This may be because both histopathological and molecular testing were performed concurrently for some patients. Indeed, at some institutions, such as that of the first author (J.C.), all NSCLC specimens are routinely tested for biomarkers as part of full histopathological characterisation.
The administration of maintenance therapy was relatively infrequent in Korea (7%), the same percentage as reported in a prior study (Sun et al., 2010) . This finding could be a reflection of local prescribing practices resulting from reimbursement policy, which stipulated that only patients showing a partial or complete remission could receive maintenance therapy. Alternatively, these findings could reflect a limitation of chart review studies, namely, that continuous maintenance therapy may be difficult to identify from the charts. Relatively low percentages were recorded also in Taiwan (10%), Italy (14%), Australia (16%) and Brazil (17%).
Median overall survival from initiation of first-line therapy ranged Median OS (95% CI) from start of 1L, months Overall 16.7 (12.6-26.2) 10.7 (8.8-12.9) 11.6 (9.2-14.6) 12.0 (9.4-14.1) 25.5 (22.6-31.3) 9.3 (7.6-11.5) practices (van der Linden et al., 2015) . Moreover, the data were collected from a convenience sample of study sites that routinely manage patients with NSCLC and therefore may not be representative of country-wide practices. Furthermore, our findings represent treatment approaches and companion diagnostics available at the time the patients were treated and hence may not be reflective of the current landscape of NSCLC management. Finally, while the total study population was large, the sample sizes within each country were relatively modest.
In conclusion, the findings of this study illustrate real-world clinical practice and treatment patterns for advanced NSCLC in seven countries in different regions of the globe. The study provides an aggregate description of treatments and outcomes prior to the introduction of PD-1 and PD-L1 inhibitors for the treatment of NSCLC. Overall, the diagnostic and treatment patterns recorded in this study were heterogeneous but largely in line with NSCLC guideline recommendations during the study years. 
